WHAT IS CLAIMED IS:

- 1. An isolated nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1.
- 2. An isolated nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4.
- 3. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is operably linked to at least one expression control sequence.
- 4. A host cell transformed or transfected with the nucleic acid molecule of claim 3.
- 5. The isolated nucleic acid molecule of claim 2 wherein said nucleic acid molecule is operably linked to at least one expression control sequence.
- 6. A host cell transformed or transfected with the nucleic acid molecule of claim 5.
- 7. An isolated nucleic acid molecule that specifically hybridizes under highly stringent conditions to the nucleotide sequence set forth in SEQ ID NO:1 or to the complement of the sequence set forth in SEQ ID NO:1.
- 8. An isolated nucleic acid molecule that specifically hybridizes under highly stringent conditions to the nucleotide sequence set forth in SEQ ID NO:4 or to the complement of the sequence set forth in SEQ ID NO:4.
- 9. An isolated nucleic acid molecule that encodes a protein having the amino acid sequence of SEQ ID NO:2.
- 10. An isolated nucleic acid molecule that encodes a protein having the amino acid sequence of SEQ ID NO:5.
- 11. An antisense oligonucleotide complementary to a mRNA corresponding to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, wherein said oligonucleotide inhibits production of KSR-2.

- 12. An antisense oligonucleotide complementary to a mRNA corresponding to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4, wherein said oligonucleotide inhibits production of KSR-2.
- 13. An isolated gene having the nucleotide sequence of SEQ ID NO:3.

Grant Ja

- 14. An isolated gene having the nucleotide sequence of SEQ ID NO:6.
- 15. An isolated allele of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1.
- 16. An isolated allele of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:3.
- 17. An isolated allele of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4.
- 18. An isolated allele of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:6.
- 19. An isolated protein having the amino acid sequence of SEQ ID NO:2, or an active fragment thereof.
- 20. An isolated protein having the amino acid sequence of SEQ ID NO:5, or an active fragment thereof.
- 21. An isolated antibody capable of binding to the protein of claim 19.
- 22. An isolated antibody capable of binding to the protein of claim 20.
- 23. A nonhuman transgenic animal in which all of the somatic and germ cells contain DNA comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1.
- 24. A nonhuman transgenic animal in which all of the somatic and germ cells contain DNA comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:3.

- 25. A method of inhibiting Cot/Tpl2-induced ERK activation in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 3.
- 26. A method of inhibiting Cot/Tpl2-induced ERK activation in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 5.
- 27. A method of inhibiting Cot/Tpl2-induced NF-κB activation in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 3.
- 28. A method of inhibiting Cot/Tpl2-induced NF-κB activation in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 5.
- 29. A method of inhibiting NF-κB-mediated gene expression in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 3.
- 30. A method of inhibiting NF-κB-mediated gene expression in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 5.
- 31. A method of inhibiting IL-8 production in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 3.
- 32. A method of inhibiting IL-8 production in a cell population comprising transforming or transfecting said cell population with the nucleic acid molecule of claim 5.
- 33. A method of inhibiting expression of KSR-2 in a cell population comprising treating said cell population with the antisense oligonucleotide of claim 11.

- 34. A method of inhibiting expression of KSR-2 in a cell population comprising treating said cell population with the antisense oligonucleotide of claim 12.
- 35. A method of identifying a compound capable of inhibiting the activity of a KSR-2 protein comprising the steps of:
 - (a) contacting a first sample containing the KSR-2 protein with one of a plurality of test compounds; and
 - (b) comparing the activity of the KSR-2 protein in the first contacted sample with that of the KSR-2 protein in a second sample not contacted with the test compound,

wherein a decrease in the activity of the KSR-2 protein in the first sample, as compared with that in the second sample, identifies the compound as an inhibitor of KSR-2 protein activity.

- 36. The method of claim 35, wherein the KSR-2 protein is the protein of claim 19.
- 37. The method of claim 35, wherein the KSR-2 protein is the protein of claim 20.
- 38. A method of identifying a compound capable of increasing the activity of a KSR-2 protein comprising the steps of:
 - (a) contacting a first sample containing the KSR-2 protein with one of a plurality of test compounds; and
 - (b) comparing the activity of the KSR-2 protein in the first contacted sample with that of the KSR-2 protein in a second sample not contacted with the test compound,

wherein an increase in the activity of the KSR-2 protein in the first sample, as compared with that in the second sample, identifies the compound as an activator of KSR-2 protein activity.

39. The method of claim 38, wherein the KSR-2 protein is the protein of claim 19.

- 40. The method of claim 38, wherein the KSR-2 protein is the protein of claim 20.
- 41. A method of inhibiting expression of KSR-2 in a cell population comprising treating said cell population with a siRNA molecule targeted to a mRNA corresponding to the isolated nucleic acid molecule of claim 1.
- 42. The method of claim 41, wherein the siRNA molecule is selected from the group consisting of siRNA molecules shown in Figure 1.
- 43. A method of inhibiting expression of KSR-2 in a cell population comprising treating said cell population with a siRNA molecule targeted to a mRNA corresponding to the isolated nucleic acid molecule of claim 2.
- 44. A siRNA molecule that inhibits the expression of KSR-2.
- 45. A siRNA molecule of claim 44, wherein the siRNA molecule is selected from the group consisting of siRNA molecules shown in Figure 1.